anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic postsurgical pain (CPSP) is increasingly recognized as a public health issue. Recent studies indicated the innate immune pathway of cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) was involved in pain regulation. However, the detailed mechanisms remain unclear. Previous studies found A1 reactive astrocytes in the spinal cord contributed to CPSP. This study aimed to investigate the roles and mechanisms of the cGAS-STING pathway in regulating the generation of A1 reactive astrocytes during CPSP. First, CPSP model was established using skin/muscle incision and retraction (SMIR) in rats. We found that cGAS-STING pathway was activated accompanied with an increase in mitochondrial DNA in the cytosol in the spinal cord following SMIR. Second, a STING inhibitor C-176 was intrathecally administrated. We found that C-176 decreased the expression of type I interferons and A1 reactive astrocytes in the spinal cord, and alleviated mechanical allodynia in SMIR rats. Third, cyclosporin A as a mitochondrial permeability transition pore blocker was intrathecally administrated. We found that cyclosporin A decreased the leakage of mitochondrial DNA and inhibited the activation of cGAS-STING pathway. Compared with C-176, cyclosporin A exhibits similar analgesic effects. The expression of type I interferons and A1 reactive astrocytes in the spinal cord were also down-regulated after intervention with cyclosporin A. Moreover, simultaneous administration of cyclosporin A and C-176 did not show synergistic effects in SMIR rats. Therefore, our study demonstrated that the cGAS-STING pathway activated by the leakage of mitochondrial DNA contributed to chronic postsurgical pain by inducing type I interferons and A1 reactive astrocytes in the spinal cord.
FIELD: medicine.SUBSTANCE: X-ray examination of a venous bed of an individual's rectum involves using 76% urografin. The inferior mesenteric vein stem and iliac vascular bundles from both sides are approached. They are catheterised and prepared by washing in 10% ammonia and distilled water. Before preparation, the inferior mesenteric vein is detected by a method of visualisation of the portal vein system. A green solution of brilliant green is inserted into its stem. The final stage is a direct X-contrast examination by fixed 12P9 Armobil-9 X-ray apparatus. 3 series of images are done. The first comparison X-ray represents plan radiography in a frontal projection of the small pelvis. The second X-ray is plan radiography in a frontal projection of the small pelvis with tight filling of the prepared bed of the rectal portal system with X-ray contrast 76% urografin. The third X-ray is plan radiography in a frontal projection of the small pelvis with tight filling of the internal iliac veins from both sides in a combination with X-ray contrast 76% urografin.EFFECT: method provides optimising the X-ray examination of the individual's rectal veins, visualising the vascular system adequately, ensuring the information concerning special characteristics of the vascular organometry, enables detecting the portocaval anastomosis by the optimum preparation of the vascular system, using urografin as the contrast substance and implementing the developed procedure of the X-ray examination.3 dwg, 1 ex
PURPOSE: A natural antibacterial composition for reducing microorganism contamination is provided to ensure excellent antibacterial and disinfection activities and to separate dental calculus. CONSTITUTION: An antibacterial composition for reducing microorganism contamination of a denture product used in oral cavity contains calcium oxide. The antibacterial composition is used in a container for containing a denture product. A denture cleansing liquid contains 0.001-1 wt% of calcium oxide. The calcium oxide is provided in the form of powder, tablet, or capsule. A method for killing bacteria for preventing bacteria proliferation is performed by dissolving the calcium oxide powder in water or dissolving in water with power, tablet or capsule formulation.
During NREM sleep acoustic stimuli will be played to decrease/modulate slow waves amplitude in a dose-dependent way (e.g. less pronounced than arm 1).
A computer-implemented method and system for managing patient healthcare and evaluating patient kidney function. A user creates a medical record for a patient, comprising a catalog of the patient's healthcare encounters.  For each encounter, a plurality of modules are provided for defining various aspects of the patient's visit including patient demographics, medical history, current medical condition, diagnosis and treatment. Based on the patient's medical record and estimated glomerular filtration rate, a plurality of patient treatment recommendations are automatically generated. Another aspect of the invention generates clinical treatment goals for the patient. 'The invention is additionally configured to generate a plurality of reports including patient medical records, physician referral letters and clinical reports comprising an aggregation of various user-defined metrics extracted globally or semi-globally from among a plurality of patient records.
Prolonged stimulation of β-adrenergic receptor (β-AR) can lead to sympathetic overactivity that causes pathologic cardiac hypertrophy and fibrosis, ultimately resulting in heart failure. Recent studies suggest that abnormal protein ubiquitylation may contribute to the pathogenesis of cardiac hypertrophy and remodeling. In this study, we demonstrated that deficiency of a deubiquitinase, Josephin domain-containing protein 2 (JOSD2), ameliorated isoprenaline (ISO)- and myocardial infarction (MI)-induced cardiac hypertrophy, fibrosis, and dysfunction both in vitro and in vivo. Conversely, JOSD2 overexpression aggravated ISO-induced cardiac pathology. Through comprehensive mass spectrometry analysis, we identified that JOSD2 interacts with Calcium-calmodulin-dependent protein kinase II (CaMKIIδ). JOSD2 directly hydrolyzes the K63-linked polyubiquitin chains on CaMKIIδ, thereby increasing the phosphorylation of CaMKIIδ and resulting in calcium mishandling, hypertrophy, and fibrosis in cardiomyocytes. In vivo experiments showed that the cardiac remodeling induced by JOSD2 overexpression could be reversed by the CaMKIIδ inhibitor KN-93. In conclusion, our study highlights the role of JOSD2 in mediating ISO-induced cardiac remodeling through the regulation of CaMKIIδ ubiquitination, and suggests its potential as a therapeutic target for combating the disease. Please check and confirm that the authors and their respective affiliations have been correctly identified and amend if necessary. All have been checked.
A cationic antimicrobial peptide (CAMP) conjugate is disclosed. The CAMP conjugate may be made by identifying a suitable carrier peptide; identifying a suitable antimicrobial agent; creating a conjugate by conjugating the peptide with the antimicrobial agent; and evaluating and refining the conjugate. The peptide may be short peptide based on the sequence of a CAMP, such as human β-defensin-3. The peptide can be directly connected to the antimicrobial agent or through a linker segment. The antimicrobial agent may be connected to the peptide or the linker segment through stable or cleavable bonding. The peptide may carry and facilitate the delivery of the conjugated antimicrobial agent to a microbe.
BACKGROUND: Peri-incisional numbness occurs frequently after Total Knee Arthroplasty (TKA), yet its impact on clinical outcomes remains controversial. With some studies reporting 100% incidence and patients often perceiving it as a minor inconvenience, its categorisation as a complication is controversial. This study investigates the prevalence and temporal changes of numbness post-TKA to refine the informed consent process and improve patient satisfaction.
MATERIAL AND METHODS: A convenience sample of patients who underwent primary cemented TKA was studied. Demographic data, scar length, tourniquet time, and WOMAC scores were collected. Patients were grouped based on time from surgery, and areas of numbness for light touch and pinprick sensations measured.
RESULTS: The study included 49 patients with a mean age of 68.9 years. While all patients reported numbness, the area decreased for both pinprick and light touch sensations over time. No significant correlation was found between WOMAC scores and the area of numbness.
DISCUSSION: Numbness post-TKA is common, and the affected area contracts over time, implying a natural healing process. The study's findings challenge the perception of numbness as a complication and emphasise the importance of informed consent in managing patient expectations.
CONCLUSIONS: 1. Postoperative numbness around the incision site following TKA is a common occurrence with minimal clinical impact on patients. 2. It is important to inform patients that this numbness will improve, although some residual numbness may remain.
PROBLEM TO BE SOLVED: To provide a new glycoprotein consisting of a glycoprotein having respectively specific contents of carbohydrate and chlorine ion and a specific molecular weight, having antiviral activity, free from side action and useful for the prophylaxis, treatment, etc., of the infection with virus such as influenza virus. SOLUTION: This new glycoprotein contains about 17.5 wt.% of carbohydrates, about 21.5 wt.% of proteins and about 28.6 wt.% of chlorine ion and has a molecular weight of about 7×10<3> wherein the mol.% of the constituent sugars are about 71.8 for glucose, about 11.0 for galacturonic acid, about 8.1 for glucuronic acid, about 3.9 for galactose, about 2.6 for mannose, about 1.4 for arabinose and about 1.3 for rhamnose. It is useful e.g. as an agent having antiviral action, free from side effect and effective for the treatment and prophylaxis of infection with virus such as influenza virus.  The glycoprotein can be produced by adding refined water to Banrankon (root of Isatis tinctoria, etc.), decocting for about 3 hr, filtering the product, concentrating the filtrate, adding ethanol to the concentrated filtrate, filtering the formed precipitate, drying the precipitate, dissolving the dried material in an aqueous solution of Nail and purifying by gel-filtration.
Control group will be given nasal oxygen (2L/min for 4h）. All other therapy measures are the same as experimental group.
The present invention relates to a blood quickening statis transforming plaster belonging to a plaster, particularly to an externally application plaster prepared from Chinese herbal medicine, which is used for treating bone fractures, injury, pustule tumors and mastoplasia. The present invention is composed of the following components (shares by weight): 5 to 7 shares of ground beetle, 5 to 7 shares of frankincense, 5 to 7 shares of myrrh, 5 to 7 shares of crinis carbonisatus, 5 to 8 shares of unguis hominis, 5 to 8 shares of musk, 50 to 70 shares of yellow wax, 50 to 70 shares of calomelas and 200 to 300 shares of sesame oil. The ground beetle, the frankincense, the myrrh, the crinis carbonisatus and the unguis hominis are pulverized and are together put into the sesame oil for frying; the yellow wax and the calomelas are put into the sesame oil so as to form a pasty object; the musk is pulverized for standby. When the pasty object is used for treatment, the musk is put into the pasty object. The present invention has obvious effect on promoting the flow of qi and blood circulation, alleviating pain and eliminating repercussion muscle. Light patients and serious patients can completely recover generally through 1 to 4 plasters which are used for treating bone fractures, injury, pustule tumors and mastoplasia. Thus, the present invention largely saves the treatment expense for the patients, and has obvious economical and social benefits.
OBJECTIVES: I. Determine the effects of priming on the granulocyte and thrombocyte nadirs produced by high dose cyclophosphamide and carboplatin in patients with advanced malignancies. II. Determine the effects of amifostine on the granulocyte and thrombocyte nadirs produced by this same regimen when administered with sargramostim primed progenitor cells. III. Determine the maximum tolerated dose of cyclophosphamide and carboplatin that can be administered with sargramostim primed progenitor cells.

OUTLINE: This is a dose escalation study. Patients receive intravenous amifostine over 10 minutes on day 0, followed by intravenous cyclophosphamide and carboplatin consecutively over 5-15 minutes. Sargramostim is administered subcutaneously on days -7 to -2 and again beginning on day 1 until absolute neutrophil count is appropriate. Course is repeated every 28 days until disease progression or unacceptable toxic effects are observed. Nonresponding patients discontinue treatment after 2 courses. Patients are treated for a maximum of 6 courses. Groups of 3-6 patients receive escalating doses of cyclophosphamide and carboplatin until the maximum tolerated dose (MTD) is determined. If dose limiting toxicity (DLT) occurs in 2 of 6 patients at a given dose level, then dose escalation ceases and the next lower dose is declared the MTD.

PROJECTED ACCRUAL: Approximately 24-30 patients will be accrued for this study within 1 year.
Malaria remains one of the most devastating infectious diseases, causing high morbidity and mortality especially in sub-Saharan Africa. The need for an accurate, simple, and inexpensive method to diagnose malaria has become increasingly urgent. Rapid diagnostic tests (RDTs), based on detection of Plasmodium antigens, may represent a more practical diagnostic tool than traditional light microscopy. This longitudinal study's objectives are (1) to evaluate the clinical performance (sensitivity, specificity, positive and negative predictive values) of RDTs, as compared with presumptive diagnosis and microscopy, for the diagnosis of malaria in children in Kampala, Uganda, and (2) to identify host and test factors that lead to false positive and false negative RDT results by comparison with polymerase chain reaction (PCR) analysis. Study subjects in this RDT study will have already been enrolled in a larger on-going longitudinal study of antimalarial drug efficacy, tolerability, and safety that began at the Kampala study site in late 2004. In the RDT study, over a one-year period, study participants' blood samples will be evaluated with the current gold standard for malaria diagnosis (microscopy) as well as two types of RDT whenever they present with a new fever episode (the first fever after study enrollment, or a fever that occurs more than 14 days after the patient's most recently diagnosed episode of malaria). As part of the on-going longitudinal drug efficacy trial, probability sampling was used to select a random sample of 600 children, who will be followed for three years for all their health-care needs. The RDT study will involve evaluation of the cohort over 12 months, beginning in approximately the third quarter of 2005. This protocol is a substudy of 04-068.
During the first stage of treatment, participants will receive four weekly clinician support sessions or 9 weeks (whichever occurs first). Early responders will be encouraged to continue app use but will discontinue clinician support sessions for 8 weeks.
PURPOSE:To obtain the title derivative whose active hydrogen atoms are all sulfated and which has a prominent property as a polyelectrolyte by controlling the pH of an aqueous organic acid solution of chitosan with an alkali to precipitate soft swollen chitosan and sulfating this chitosan. CONSTITUTION:The pH of a solution of a chitosan of formula I (wherein n is 1-12000; R1 is H or a group of formula II, and R2, R3 and R4 are each H) in an aqueous solution of an organic acid (e.g. acetic acid) is controlled with an alkali (e.g. NaOH) to precipitate soft swollen chitosan. This chitosan is sulfated to obtain a sulfated chitosan derivative of formula I (wherein n is as defined above, R2 is a group of formula III (wherein M is H, NH4 or a metallic ion) when R1 is H, or is H when R1 is formula II; R3 and R4 are each a group of formula III). Although sulfated chitosans synthesized by conventional processes are insufficiently sulfated ones, the sulfated chitosan derivative synthesized by this process is one whose active hydrogen atoms are all sulfated, and can fully exhibit its effect as a polyelectrolyte. This derivative can be used as a sequestering agent in the textile industry and the perfume and cosmetic industry or as a buffer in the pharmaceutical industry.
Participants randomised to REBUILD-SM will receive the self-management package as well as the RE-BUILD app. Structured self-management support via telephone or Zoom call will be provided 4 times during the 12-week intervention period.
The present invention relates to a medicinal pill strengthening body resistance and treating hemiplegia, which is a Chinese patent medicine treating apoplexy and hemiplegia. The present invention is prepared into an oral Chinese patent medicine by adopting nux vomica, largeleaf gentian root, twotooth achyranthes root, scorpion, astragalus root, garter snake, earthworm, reticulate millettia, liquoric root, pangolin scales, gastrodia tuber, nacre, cornu saigae tatariace powder, etc. as raw materials. The present invention has the advantages that the formula of the present invention has been studied with great concentration since 1980, more than 200 times of experiments were performed on self in 1985, and the formula was used for treating diseases in 1989. The present invention has the functions of blood circulation improvement, cerebrovascular resistance reudction and blood stream increasing. The present invention mainly treats hemiplegia and sequela thereof which are caused by cardio-cerebrovascular diseases, such as hemiplegia, facial hemiparalysis, inarticulacy, difficult action, numbness of the limbs, etc. In more than ten years in clinic, more than 6000 patients are cured, and the cure rate reaches over 96.5%. The present invention has the advantages of simple preparing technology, little toxic side effect, good curative effect and convenient taking.
Hyperglycaemia affects more than 30% of adults hospitalized for non-critical illness and is associated with an increased risk of adverse clinical outcomes. Insulin therapy is widely used for its safety and efficacy. However, given the growing availability of new drugs and new classes of antidiabetic agents with benefits beyond glycaemic control, challenges arise regarding their use in the hospital setting. This article aims to review and summarize the most recently available evidence and recommendations on the role of non-insulin antidiabetic agents in the management of hyperglycaemia in hospitalized patients. Insulin therapy remains the method of choice. Dipeptidyl peptidase 4 inhibitors can be considered in mild to moderate hyperglycaemia. Glucagon-like peptide 1 receptor agonists have recently shown promising results, with high efficacy in glycaemic control and low risk of hypoglycaemia. There are concerns regarding the increased risk of acidosis with metformin use, especially in cases of acute illness, although there is no evidence to support its suspension in selected patients with relative clinical stability. Sodium-glucose cotransporter-2 inhibitors should be discontinued in clinical situations that may predispose to ketoacidosis, including episodes of acute illness. The hospital use of sulfonylureas and thiazolidinediones is not advised.
The invention discloses tryptanthrin containing 1,2, 3-triazole and a preparation method and application thereof. The preparation method comprises the step of connecting 2-bromomethyl-8-fluorotryptanthrin with 1,2, 3-triazole to obtain tryptanthrin containing 1,2, 3-triazole. Carrying out reflux reaction on 2-bromomethyl-8-fluorotryptanthrin and propiolic acid in a mixed solvent of acetone and water in the presence of sodium azide and cuprous iodide to obtain a crude product, and carrying out column chromatography separation on the crude product to obtain the 2- (1,2, 3-triazolylmethyl) -8-fluorotryptanthrin. The 1,2, 3-triazole can play a plurality of non-covalent bond functions, is widely used for designing new drug molecules and can enhance the pharmacological activity of the compounds. The tryptanthrin derivative can be used for treating pathological characteristic diseases with IDO mediated tryptophan metabolic pathway and has wide application prospect. The preparation method of the invention has simple operation and mild condition, and is easy for industrial production.
Cardio-metabolic traits have been reported to be associated with the development of sepsis. It is, however, unclear whether these co-morbidities reflect causal associations, shared genetic heritability, or are confounded by environmental factors. We performed three analyses to explore the relationships between cardio-metabolic traits and sepsis. Mendelian randomization (MR) study to evaluate the causal effects of multiple cardio-metabolic traits on sepsis. Global genetic correlation analysis to explore the correlations between cardio-metabolic traits and sepsis. Local genetic correlation (GC) analysis to explore shared genetic heritability between cardio-metabolic traits and sepsis. Some loci were further examined for related genes responsible for the causal relationships. Genetic associations were obtained from the UK Biobank data or published large-scale genome-wide association studies with sample sizes between 200,000 to 750,000. In MR, we found causality between BMI and sepsis (OR: 1.53 [1.4-1.67]; p < 0.001). Body mass index (BMI), which is confirmed by sensitivity analyses and multivariable MR adjusting for confounding factors. Global GC analysis showed a significant correlation between BMI and sepsis (rg = 0.55, p < 0.001). More cardio-metabolic traits were identified to be correlated to the sepsis onset such as CRP (rg = 0.37, p = 0.035), type 2 diabetes (rg = 0.33, p < 0.001), HDL (rg = - 0.41, p < 0.001), and coronary artery disease (rg = 0.43, p < 0.001). Local GC revealed some shared genetic loci responsible for the causality. The top locus 1126 was located at chromosome 7 and comprised genes HIBADH, JAZF1, and CREB5. The present study provides evidence for an independent causal effect of BMI on sepsis. Further detailed analysis of the shared genetic heritability between cardio-metabolic traits and sepsis provides the opportunity to improve the preventive strategies for sepsis.
Worldwide, lung cancer is the most commonly diagnosed cancer. In NSCLC the most prevalent actionable driver mutations result in the activation of epidermal growth factor receptor (EGFR). Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody that targets the extracellular domain of both EGFR and MET and can inhibit tumor growth driven by EGFR and mesenchymal-epithelial transition (MET) receptors. Lazertinib inhibits primary activating Exon 19dell and Exon 21 L858R substitution EGFR mutations, and the EGFR T790M+ resistance mutation. The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B). The study consists of 3 phases: Screening Phase, Treatment Phase and Follow-up Phase. Participants will undergo response evaluation criteria in solid tumors (RECIST 1.1), pharmacokinetics, and safety evaluations (adverse events, laboratory tests, vital sign measurements, physical examinations).